Non-invasive Prenatal Diagnosis of Monogenic Disorders by Linked-reads Technology

Objectives:

The description of cell-free fetal DNA in maternal plasma offered the possibility of a non invasive approach for prenatal diagnosis (Non Invasive Prenatal Diagnosis, NIPD). However, only a small fraction of total cell-free DNA is of fetal origin, and its study widened only recently with the development of new technologies, such as digital PCR and Massively Parallel Sequencing.

Circulating fetal cells (CFC) represent a promising approach, but need further development before routine implementation To date, clinical applications are limited to Non Invasive Prenatal Testing for fetal aneuploidy and non invasive detection of fetal-specific genomic regions, for example fetal sex determination or fetal RHD genotyping, or more recently de novo mutations that can be suspected after echographic findings, such as achondroplasia. Yet, NIPD of maternally-inherited monogenic diseases remains challenging, for the fetal allele is hidden within a large amount of identical maternal sequences. Some publications report successful NIPD of maternally-inherited monogenic diseases, but only on case reports or small cohorts, without a standardized protocol and control of statistical risks.

In this study, we aim :

• to develop a new non invasive approach to Prenatal Diagnosis using both direct and indirect strategy by Massively Parallel Sequencing,
• to identify and characterize CFC.

Methods:

We recently acquired the Chromium™ technology (10XGenomics™). This approach, relying on microfluidic-based linked-read sequencing, allows direct haplotype phasing from long input DNA molecules, in this case parental genomic DNA. It is therefore possible to identify the mutant-linked haplotype for each parent and deduce fetal status with concomitant plasma DNA analysis.

We plan to include couples at risk of transmitting cystic fibrosis, during genetic counseling for prenatal diagnosis (PND). Non invasive analysis will be performed concomitantly to conventional PND, which will be performed on invasive fetal sample. After sequencing, we will use a new analysis algorithm that allows strict control of statistical risk.

Furthermore, we plan on using the Chromium Single Cell Solution (10XGenomics™) to isolate CFC. This approach allows analysis of single cell gene expression from thousands cells in a sample.

Expected results:

In this first study, we wish to include 20 couples in the course of 12 months, which will represent the largest cohort published to date.

We aim to assess feasibility of this new promising technology of Universal Haplotyping by linked-read sequencing in the context of NIPD of monogenic diseases, in terms of result accuracy as well as analysis time and technical cost. This straightforward protocol opens perspectives for a first-intention non invasive approach of prenatal diagnosis of familial monogenic diseases.

The Single Cell Solution will also enable us to differentiate the cell types circulating in maternal blood, and to identify molecular markers to isolate CFC.

Inclusion criteria

• Pregnancies at 25% risk of being affected by Cystic Fibrosis with previously identified pathogenic variants
• Couple asking for invasive prenatal diagnosis
• Pregnancy at 8 weeks of gestation or later

Exclusion criteria

• Couple not asking for prenatal diagnosis
• No signed consent obtained